O	0	10	Randomized
O	10	11	,
O	12	23	Multicenter
O	23	24	,
O	25	32	Placebo
O	32	33	-
O	33	43	Controlled
O	44	52	Clinical
O	53	58	Trial
O	59	61	of
B-intervention	62	72	Duloxetine
O	73	79	Versus
B-control	80	87	Placebo
O	88	91	for
B-condition	92	101	Aromatase
I-condition	102	111	Inhibitor
I-condition	111	112	-
I-condition	112	122	Associated
I-condition	123	134	Arthralgias
O	135	137	in
O	138	143	Early
O	143	144	-
O	144	149	Stage
O	150	156	Breast
O	157	163	Cancer
O	163	164	:
O	165	169	SWOG
O	170	175	S1202
O	175	176	.

O	177	184	Purpose
O	185	194	Adherence
O	195	197	to
O	198	207	aromatase
O	208	217	inhibitor
O	218	219	(
O	219	221	AI
O	221	222	)
O	223	230	therapy
O	231	234	for
O	235	240	early
O	240	241	-
O	241	246	stage
O	247	253	breast
O	254	260	cancer
O	261	263	is
O	264	271	limited
O	272	274	by
O	275	277	AI
O	277	278	-
O	278	288	associated
O	289	304	musculoskeletal
O	305	313	symptoms
O	314	315	(
O	315	320	AIMSS
O	320	321	)
O	321	322	.

O	323	333	Duloxetine
O	334	336	is
O	337	339	US
O	340	344	Food
O	345	348	and
O	349	353	Drug
O	354	368	Administration
O	369	377	approved
O	378	381	for
O	382	391	treatment
O	392	394	of
O	395	403	multiple
O	404	411	chronic
O	412	416	pain
O	417	426	disorders
O	426	427	.

O	428	430	We
O	431	443	hypothesized
O	444	448	that
O	449	458	treatment
O	459	461	of
O	462	467	AIMSS
O	468	472	with
O	473	483	duloxetine
O	484	489	would
O	490	497	improve
O	498	505	average
O	506	511	joint
O	512	516	pain
O	517	525	compared
O	526	530	with
O	531	538	placebo
O	538	539	.

O	540	547	Methods
O	548	552	This
O	553	563	randomized
O	563	564	,
O	565	571	double
O	571	572	-
O	572	577	blind
O	577	578	,
O	579	584	phase
O	585	588	III
O	589	594	trial
O	595	603	included
B-eligibility	604	606	AI
I-eligibility	606	607	-
I-eligibility	607	614	treated
I-eligibility	615	629	postmenopausal
I-eligibility	630	635	women
I-eligibility	636	640	with
I-eligibility	641	646	early
I-eligibility	646	647	-
I-eligibility	647	652	stage
I-eligibility	653	659	breast
I-eligibility	660	666	cancer
I-eligibility	667	670	and
I-eligibility	671	674	who
I-eligibility	675	678	had
I-eligibility	679	686	average
I-eligibility	687	692	joint
I-eligibility	693	697	pain
I-eligibility	698	703	score
I-eligibility	704	706	of
I-eligibility	707	708	≥
I-eligibility	709	710	4
I-eligibility	711	714	out
I-eligibility	715	717	of
I-eligibility	718	720	10
I-eligibility	721	725	that
I-eligibility	726	735	developed
I-eligibility	736	738	or
I-eligibility	739	747	worsened
I-eligibility	748	753	since
I-eligibility	754	756	AI
I-eligibility	757	764	therapy
I-eligibility	765	775	initiation
O	775	776	.

O	777	785	Patients
O	786	790	were
O	791	799	randomly
O	800	808	assigned
O	809	810	1
O	810	811	:
O	811	812	1
O	813	815	to
O	816	826	duloxetine
O	827	829	or
O	830	837	placebo
O	838	841	for
O	842	844	13
O	845	850	weeks
O	850	851	.

O	852	855	The
O	856	863	primary
O	864	867	end
O	868	873	point
O	874	877	was
B-outcome-Measure	878	885	average
I-outcome-Measure	886	891	joint
I-outcome-Measure	892	896	pain
I-outcome-Measure	897	904	through
I-outcome-Measure	905	907	12
I-outcome-Measure	908	913	weeks
O	913	914	,
O	915	923	examined
O	924	929	using
O	930	943	multivariable
O	944	950	linear
O	951	956	mixed
O	957	963	models
O	963	964	,
O	965	973	adjusted
O	974	977	for
O	978	992	stratification
O	993	1000	factors
O	1001	1002	(
O	1002	1010	baseline
O	1011	1015	pain
O	1016	1021	score
O	1022	1024	of
O	1025	1026	4
O	1027	1029	to
O	1030	1031	6
O	1032	1033	v
O	1034	1035	7
O	1036	1038	to
O	1039	1041	10
O	1042	1045	and
O	1046	1051	prior
O	1052	1058	taxane
O	1059	1062	use
O	1062	1063	)
O	1063	1064	.

O	1065	1075	Clinically
O	1076	1087	significant
O	1088	1094	change
O	1095	1097	in
O	1098	1105	average
O	1106	1110	pain
O	1111	1114	was
O	1115	1122	defined
O	1123	1125	as
O	1126	1127	a
O	1128	1129	≥
O	1130	1131	2
O	1131	1132	-
O	1132	1137	point
O	1138	1146	decrease
O	1147	1151	from
O	1152	1160	baseline
O	1160	1161	.

O	1162	1169	Results
O	1170	1172	Of
B-total-participants	1173	1176	299
O	1177	1185	enrolled
O	1186	1194	patients
O	1194	1195	,
B-intervention-participants	1196	1199	127
O	1200	1208	patients
O	1209	1216	treated
O	1217	1221	with
O	1222	1232	duloxetine
O	1233	1236	and
B-control-participants	1237	1240	128
O	1241	1244	who
O	1245	1253	received
O	1254	1261	placebo
O	1262	1266	were
O	1267	1276	evaluable
O	1277	1280	for
O	1281	1284	the
O	1285	1292	primary
O	1293	1301	analysis
O	1301	1302	.

O	1303	1305	By
O	1306	1308	12
O	1309	1314	weeks
O	1314	1315	,
O	1316	1319	the
B-outcome	1320	1327	average
I-outcome	1328	1333	joint
I-outcome	1334	1338	pain
I-outcome	1339	1344	score
O	1345	1348	was
O	1349	1350	0
O	1350	1351	.
O	1351	1353	82
O	1354	1360	points
O	1361	1366	lower
O	1367	1370	for
O	1371	1379	patients
O	1380	1383	who
O	1384	1392	received
O	1393	1403	duloxetine
O	1404	1412	compared
O	1413	1417	with
O	1418	1423	those
O	1424	1427	who
O	1428	1436	received
O	1437	1444	placebo
O	1445	1446	(
O	1446	1448	95
O	1448	1449	%
O	1450	1452	CI
O	1452	1453	,
O	1454	1455	-
O	1455	1456	1
O	1456	1457	.
O	1457	1459	24
O	1460	1462	to
O	1463	1464	-
O	1464	1465	0
O	1465	1466	.
O	1466	1468	40
O	1468	1469	;
O	1470	1471	P
O	1472	1473	=
O	1474	1475	.
O	1475	1479	0002
O	1479	1480	)
O	1480	1481	.

O	1482	1489	Similar
O	1490	1498	patterns
O	1499	1503	were
O	1504	1512	observed
O	1513	1516	for
B-outcome	1517	1522	worst
I-outcome	1523	1528	joint
I-outcome	1529	1533	pain
O	1533	1534	,
B-outcome	1535	1540	joint
I-outcome	1541	1550	stiffness
O	1550	1551	,
B-outcome	1552	1556	pain
I-outcome	1557	1569	interference
O	1569	1570	,
O	1571	1574	and
B-outcome	1575	1586	functioning
O	1586	1587	.

B-outcome	1588	1593	Rates
I-outcome	1594	1596	of
I-outcome	1597	1604	adverse
I-outcome	1605	1611	events
I-outcome	1612	1614	of
I-outcome	1615	1618	any
I-outcome	1619	1624	grade
O	1625	1629	were
O	1630	1636	higher
O	1637	1639	in
O	1640	1643	the
O	1644	1654	duloxetine
O	1654	1655	-
O	1655	1662	treated
O	1663	1668	group
O	1669	1670	(
B-iv-bin-percent	1670	1672	78
I-iv-bin-percent	1672	1673	%
O	1674	1675	v
B-cv-bin-percent	1676	1678	50
I-cv-bin-percent	1678	1679	%
O	1679	1680	)
O	1680	1681	;
B-outcome	1682	1687	rates
I-outcome	1688	1690	of
I-outcome	1691	1696	grade
I-outcome	1697	1698	3
I-outcome	1699	1706	adverse
I-outcome	1707	1713	events
O	1714	1718	were
O	1719	1726	similar
O	1726	1727	.

O	1728	1738	Conclusion
O	1739	1746	Results
O	1747	1749	of
O	1750	1759	treatment
O	1760	1764	with
O	1765	1775	duloxetine
O	1776	1779	for
O	1780	1785	AIMSS
O	1786	1790	were
O	1791	1799	superior
O	1800	1802	to
O	1803	1808	those
O	1809	1811	of
O	1812	1819	placebo
O	1820	1825	among
O	1826	1831	women
O	1832	1836	with
O	1837	1842	early
O	1842	1843	-
O	1843	1848	stage
O	1849	1855	breast
O	1856	1862	cancer
O	1862	1863	,
O	1864	1872	although
O	1873	1875	it
O	1876	1884	resulted
O	1885	1887	in
O	1888	1892	more
O	1893	1901	frequent
O	1902	1905	low
O	1905	1906	-
O	1906	1911	grade
O	1912	1922	toxicities
O	1922	1923	.
